References


20. Schlander M: *Health economic evaluation of medical interventions: answering questions people are unwilling to ask?* 5th World Congress, International Health


60. O’Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of Desimipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. 

61. Meropol SB. Valuing reduced antibiotic use for pediatric acute otitis media. 


68. McGregor M. What decision-makers want and what they have been getting. *Value in Health* 2006; 9 (3): 181-185


87. Schlander M, Richardson J. The evolving health economics evaluation paradigm and
the role of the QALY. *Value in Health* 2009; 12 (7): A400.

88. Schlander M. The use of cost-effectiveness by the National Institute for Health and
Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process. *Journal
of Medical Ethics* 2008; 34: 534-539.

89. Stolk EA, Busschbach JJ, Caffa M, Meuleman EJ, Rutten FF. Cost utility analysis of
sildenafil compared with papaverine-phenolamine injections. *British Medical

90. Culyer AJ. Commodities, characteristics of commodities, characteristics of people,
utilities, and the quality of life. In: Baldwin S (Editor) *Quality of Life: Perspectives

91. Nussbaum MC. Capabilities as fundamental entitlements: Sen and social justice.


92. Coast J, Smith RD, Lorgelly P. Welfarism, extra-welfarism and capability: the spread


94. Brock DW. Ethical issues in the use of cost effectiveness analysis for the
prioritisation of health care resources. In: Anand S, Peter F, Sen A (Editors) *Public

95. Schlander M. *Health Technology Assessments by the National Institute for Health


104. Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat?

The case of enzyme replacement therapy for mucopolysaccharidosis VI. *Current Medical Research and Opinion* 2009; 25 (5): 1285-1293.

105. Le Pen C. Is there a “continental” view of health economics evaluation?


108. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG).


